Apolipoprotein KV domain (67 – 77) YTMNPRKLFDY-acid
Apolipoprotein KV domain (67 – 77) corresponds to the active region of human apolipoprotein A (ApoA) kringle5- like domain; this sequence can inhibit angiogenesis.
Catalogue number crb1000161 Molecular Weight 1447.66 Sequence (one letter code) YTMNPRKLFDY-acid Sequence (three letter code)
Purity >95% References
Kalaivani and Jaleel (2020). Apolipoprotein(a), an enigmatic anti-angiogenic glycoprotein in human plasma: A curse or cure? Pharmacol Res., 58: 104858. PMID: 32430285.
Yi et al., (2009). A novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c-Src phosphorylation in VEGF-induced human umbilical endothelial cells. Int. J. Cancer Res., 124(4): 843. https://doi.org/10.1002/ijc.24027.
Manufactured in: United Kingdom
Vascular lipid deposition and altered lipid profiles are typical when unregulated angiogenesis is occurring, it is often seen in vascular disorders such as cancer and atherosclerosis. Apolipoprotein a (ApoA) functions as part of the lipid transporter complex high-density lipoproteins (HDL) to ensure lipid homeostasis and therefore the balance of angiogenesis. Within ApoA the Kringle5 (KV) domain (67 – 77), also known as KV11, has been identified as the region of ApoA that exerts anti-angiogenic effect. KV11 was shown in tumour cells to inhibit angiogenesis and consequently inhibits tumour progression. KV11 targets the angiogenesis c-Src/ERK pathway by blocking the activation signals received from vascular endothelial growth factor (VEGF). KV11 provides a new research potential for an anti-angiogenesis and anti-tumour therapeutic agent.